Celebrating 20 Years of IP Excellence

High Court of Himachal Pradesh grants Boehringer Ingelheim an interim injunction against Eris Lifesciences for patent infringement of diabetes drug Empagliflozin

Boehringer secures Patent Injunction for its Diabetes Drug – Empagliflozin

On May 30, 2024, the High Court of Himachal Pradesh granted an interim injunction to Boehringer Ingelheim, restraining Eris Lifesciences from manufacturing, selling, or marketing Empagliflozin tablets due to patent infringement. The court emphasized the importance of maintaining scientific integrity and upheld the validity of Boehringer’s patent. Continue Reading Boehringer secures Patent Injunction for its Diabetes Drug – Empagliflozin

Read more